Japan · Hospital & health care startup
Japan · HIROTSU Bio Science (HIROTSU)
HIROTSU Bio Science Inc.
Funding reportedLast round: Undisclosed round
About HIROTSU Bio Science (HIROTSU)
HIROTSU Bio Science Inc.
is a Japanese biotechnology company dedicated to the research, development, and sales of innovative cancer screening technologies. The company specializes in using nematodes and their olfactory sensors to create advanced diagnostic tools. Its flagship product, N-NOSE, is the world’s first urine-based cancer screening test that estimates cancer risk. The company offers a range of services, including N-NOSE for Business, which provides corporate cancer screening programs to support employee health initiatives. HIROTSU Bio Science also delivers medical-related information and support services for healthcare professionals, enhancing the adoption and use of its testing technology. The company aims to foster early cancer detection and promote health and peace of mind for individuals and organizations alike.
What company datasets say HIROTSU Bio Science (HIROTSU) raised
Funding, as reported
The company, in detail
What they build
Known for
health caremedical innovationhealthcare solutionshealth diagnosticssocietal impactmedical researchmedical testingbiomedicinecancer screeninghospital & health caresocietal contributionn-nose cancer detectionb2cbiomedical partnershipshealthbiotechnology
Built with from their website
Google Tag ManagerWordPress.orgSakura InternetPWAYouTubeCloudFlareViewport MetaGoogle Font APIMicrosoft ExchangeMySQL
+8 more
Microsoft 365 Apps & ServicesMobile FriendlyOpen GraphjQueryjQuery UISwiperjQuery CDNGoogle Analytics
- Sector
- Hospital & health care
- Industry code
- NAICS 325413, 541714, SIC 8731, 3841
- Region
- Tokyo
- Full record
- Every detail in the company directory
Hospital & health care in Japan
Startups like it
Is this your company?
Add your raise, your deck and your story, and put HIROTSU Bio Science (HIROTSU) in front of investors. Or tell us what we have wrong.